SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
A box of Johnson & Johnson's Janssen COVID-19 vaccine doses are pictured at Grubb's Pharmacy on Capitol Hill in this file photo. On Tuesday, the CDC and FDA issued an official recommendation to pause use of the Johnson & Johnson vaccine out of what agencies called "an abundance of caution," citing a "rare and severe type of blood clot" in some individuals after receiving the single-dose shot. (Photo: Tom Williams/CQ-Roll Call, Inc via Getty Images)
'Out of Abundance of Caution,' FDA and CDC Recommend Pause of Johnson & Johnson Covid-19 Vaccine
Out of 6.8 million doses administered thus far, the agencies said they are "reviewing data involving 6 reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the vaccine."
Apr 13, 2021
This is a breaking news story... Check back for possible updates...
The U.S. Centers for Disease Control and the Food and Drug Administration on Tuesday issued an official recommendation to pause the use of Johnson & Johnson's Covid-19 vaccine out what the agencies called an "abundance of caution," citing a "rare and severe type of blood clot" that some individuals have experienced as a side effect following the single-shot dose.
As of April 12, according to a public statement by the two agencies released via Twitter, more than 6.8 million doses of the J&J vaccine have been administered in the United States. Of those, the agency said it is now "reviewing data involving 6 reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare."
"Treatment of this specific type of blood clot is different from the treatment that might typically be administered," the agencies noted.
As part of the review, the CDC will convene a Wednesday meeting of the Advisory Committee on Immunization Practices (ACIP) "to further review these cases and assess their potential significance." FDA, the statement added, will also review the CDC analysis as part of its separate investigation into these cases.
"Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot," tweeted the FDA.
"Vaccine safety is a top priority for the federal government," the agencies added, "and we take all reports of health problems following COVID-19 vaccination very seriously."
The CDC and FDA will be hosting a live audio press conference at 10:00 are ET to detail the matter and update the public on the decision.
Listen to the press conference:
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
This is a breaking news story... Check back for possible updates...
The U.S. Centers for Disease Control and the Food and Drug Administration on Tuesday issued an official recommendation to pause the use of Johnson & Johnson's Covid-19 vaccine out what the agencies called an "abundance of caution," citing a "rare and severe type of blood clot" that some individuals have experienced as a side effect following the single-shot dose.
As of April 12, according to a public statement by the two agencies released via Twitter, more than 6.8 million doses of the J&J vaccine have been administered in the United States. Of those, the agency said it is now "reviewing data involving 6 reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare."
"Treatment of this specific type of blood clot is different from the treatment that might typically be administered," the agencies noted.
As part of the review, the CDC will convene a Wednesday meeting of the Advisory Committee on Immunization Practices (ACIP) "to further review these cases and assess their potential significance." FDA, the statement added, will also review the CDC analysis as part of its separate investigation into these cases.
"Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot," tweeted the FDA.
"Vaccine safety is a top priority for the federal government," the agencies added, "and we take all reports of health problems following COVID-19 vaccination very seriously."
The CDC and FDA will be hosting a live audio press conference at 10:00 are ET to detail the matter and update the public on the decision.
Listen to the press conference:
This is a breaking news story... Check back for possible updates...
The U.S. Centers for Disease Control and the Food and Drug Administration on Tuesday issued an official recommendation to pause the use of Johnson & Johnson's Covid-19 vaccine out what the agencies called an "abundance of caution," citing a "rare and severe type of blood clot" that some individuals have experienced as a side effect following the single-shot dose.
As of April 12, according to a public statement by the two agencies released via Twitter, more than 6.8 million doses of the J&J vaccine have been administered in the United States. Of those, the agency said it is now "reviewing data involving 6 reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare."
"Treatment of this specific type of blood clot is different from the treatment that might typically be administered," the agencies noted.
As part of the review, the CDC will convene a Wednesday meeting of the Advisory Committee on Immunization Practices (ACIP) "to further review these cases and assess their potential significance." FDA, the statement added, will also review the CDC analysis as part of its separate investigation into these cases.
"Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot," tweeted the FDA.
"Vaccine safety is a top priority for the federal government," the agencies added, "and we take all reports of health problems following COVID-19 vaccination very seriously."
The CDC and FDA will be hosting a live audio press conference at 10:00 are ET to detail the matter and update the public on the decision.
Listen to the press conference:
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.